Skip to Main Content

Advertisement

Skip Nav Destination

NMDP Enrolls First OPTIMIZE Patient

April 3, 2024

May 2024

In February, NMDP (formerly known as the National Marrow Donor Program and Be The Match) enrolled the first patient in the OPTIMIZE trial. The trial is evaluating a reduced dose of post-transplant cyclophosphamide (PTCy) in patients with blood cancers who have received peripheral blood hematopoietic cells from mismatched unrelated donors (MMUD).

Sponsored by NMDP through the Center for International Blood and Marrow Transplant Research (CIBMTR), the study aims to prevent graft-versus-host disease (GVHD) while reducing the severe side effects associated with higher doses of PTCy.

“We are encouraged by the OPTIMIZE trial’s potential to transform patient care in blood cancer treatment,” said Jeffery J. Auletta, MD, senior vice president of Health Equity at NMDP and chief scientific director at CIBMTR. “This trial represents a pivotal step forward, laying the groundwork for future research using innovative strategies for preventing and treating not only [GVHD], but also malignant disease relapse as well as applying MMUD transplant to cure non-malignant diseases like sickle cell disease.”

Goals for the trial include improving quality of life and survival, decreasing relapse via increased myeloablative conditioning, and supporting future trials’ use of reduced-dose PTCy.

Source: Global Newswire, February 20, 2024.

 

Advertisement

Connect with us:

CURRENT ISSUE
May 2024

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement